334 related articles for article (PubMed ID: 33154779)
1. Latest evidence on immunotherapy for cholangiocarcinoma.
Guo X; Shen W
Oncol Lett; 2020 Dec; 20(6):381. PubMed ID: 33154779
[TBL] [Abstract][Full Text] [Related]
2. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J; Lv X; Zhang Z; Huang Z; Zhang E
Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
[TBL] [Abstract][Full Text] [Related]
3. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
4. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy.
Sarantis P; Tzanetatou ED; Ioakeimidou E; Vallilas C; Androutsakos T; Damaskos C; Garmpis N; Garmpi A; Papavassiliou AG; Karamouzis MV
Am J Transl Res; 2021; 13(12):13246-13260. PubMed ID: 35035673
[TBL] [Abstract][Full Text] [Related]
6. Cancer review: Cholangiocarcinoma.
Ghouri YA; Mian I; Blechacz B
J Carcinog; 2015; 14():1. PubMed ID: 25788866
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes.
Li C; Bie L; Chen M; Ying J
Explor Target Antitumor Ther; 2023; 4(6):1310-1327. PubMed ID: 38213535
[TBL] [Abstract][Full Text] [Related]
8. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma in the Era of Immunotherapy.
Manthopoulou E; Ramai D; Dhar J; Samanta J; Ioannou A; Lusina E; Sacco R; Facciorusso A
Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376451
[TBL] [Abstract][Full Text] [Related]
10. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
11. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
[TBL] [Abstract][Full Text] [Related]
12. Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature.
He MY; Yan FF; Cen KL; Shen P
World J Clin Cases; 2022 Nov; 10(32):11889-11897. PubMed ID: 36405269
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.
Macias RI
ISRN Hepatol; 2014; 2014():828074. PubMed ID: 27335842
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
16. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
17. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
18. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
[TBL] [Abstract][Full Text] [Related]
19. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma.
Trifylli EM; Koustas E; Papadopoulos N; Sarantis P; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Karamouzis MV
Life (Basel); 2022 Apr; 12(5):. PubMed ID: 35629333
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]